Naslov
Association of fibrinogen and plasmin inhibitor, but not coagulation factor XIII gene polymorphisms with coronary artery disease

Autori
Bronić, Ana ; Ferenčak, Goran, Bernat Robert, Leniček Krleža, Jasna, Dumić, Jerka ; Dabelić, Sanja

Izvornik
Journal of medical biochemistry (1452-8258) 40 (2021), 2; 138-149

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
coronary artery disease ; FXIII ; fibrinogen ; genotyping ; plasmin inhibitor ; polymorphisms

Sažetak
Background: In the final phase of clot formation, fibrinogen constitutes frame, whereas factor XIII (FXIII) active form is responsible for the covalent cross-linking of fibrin fibres and plasmin inhibitor (PI), thus contributing to clot stability. It could be expected that any change of coagulation factors’ structure affects the clot formation and modulates the atherothrombotic risk. The aim was to determine the frequency of four single nucleotide polymorphisms: (i) A > G in codon 312 of the fibrinogen alpha-chain gene (rs6050, Thr312AlaFGA), (ii) C > T at position 10034 of the 3-untranslated region in the fibrinogen gamma-chain gene (rs2066865, 10034C > T FGG), (iii) C > T in codon 564 of the FXIII-A subunit gene (rs5982, Pro564LeuFXIII-A), and (iv) C > T in codon 6 of the plasmin inhibitor gene (rs2070863, Arg6TrpPI) in Croatian patients and their association with coronary artery disease (CAD). Methods: We performed the unrelated case- control association study on the consecutive sample of patients 18 or more years old, who had undergone coronary angiography for investigation of chest pain and suspected CAD. The cases were patients with confirmed CAD (N = 201), and the controls were the subjects with no CAD (N = 119). Samples were genotyped using PCR-RFLP analysis. Results: Observed frequencies of the rare alleles of Thr312Ala FGA, 10034C > T FGG, Leu564Pro FXIII- A and Arg6Trp PI polymorphisms were 21%, 17%, 14%, 20%, respectively. Patients with 10034C > T FGG CC genotype had 3.5 times (95% CI 1.02–12.03) higher adjusted odds for CAD than patients with 10034C > TFGG TT genotype. Patients with Arg6Trp PI CC genotype had 3.86 times (95% CI 1.23–12.12) higher odds for CAD than patients with Arg6Trp PI TT genotype. It seems that those genotype-related higher odds are also male-gender related. No difference was observed regarding any other investigated polymorphism. Conclusions: Our finding suggests that 10034C > T FGG and Arg6Trp PI are associated with CAD.

Izvorni jezik
Engleski

Znanstvena područja
Farmacija

POVEZANOST RADA